I just read this e-book, simply because, according to my friend this book is written by some of the ingenious individuals who foresaw and also profited even from the financial collapse. - Sunita
I heard people are using this e-book as a Self-help guide to investing. I recently finished studying it, and never have experimented with any of the strategies; however they all appear to make sense. - Rajiv
A fantastic guide overall. Quite different from almost all other value investing publications because it concentrates on finding unique scenarios that are best to invest in. - Alexis
This particular e-book really opened up my eyes to some fresh opportunities and possibilities that while investing I should be looking for. Once you have read this traditional value investing book you will learn a lot. - Kavita
I really like the writer of this book. It is simple, properly explained, amusing, relevant, and incredibly well planned. This particular e-book is really a holy bible for dealing with unique circumstances in the market. - Saurabh

History of Wyeth Ltd.

1947

- The Comp. was incorporated on 20th September under the name 'Lederle Laboratories [Indias] Ltd.' as a private limited company. The name was changed to Cyanamid India Ltd., on 31st October, 1962. It became a full fledged public limited Comp. in November 1965. The Company Manufacture drugs, pharmaceuticals & agro-chemicals, insecticides & animal health products. Initially, the Comp. was a wholly owned subsidiary of American Cyanamid Co., U.S.A.

1961

- A basic fermentation plant was built, for manufacture, mainly from indigenous raw materials, of basic bulk drugs required for the formulations of Lederle antibiotics, viz., Aureomycin, Achromycin and Ledermycin.

1962

- The Atul Products Ltd., Ahmedabad acquired by subscribing to a fresh issue of share, a 24% interest which was increased [also by subscription to fresh issue of sharess] to 35% in 1963.

1963

- The Agricultural division malathion insecticide plant at Atul, Valsad was commissioned. A wide range of pesticides as well as animal health products were introduced thereafter.

1964

- Since incorporation upto the end of year, the Comp. issued the following shares:

- [is] 1,502 No. of Equity shares of Rs 100 each for cash at par to American Cyanamid Co. U.S.A., in 1947,

- [iis] 15,160 No. of equity shares of Rs 100 each without payment in cash to American Cyanamid Co., U.S.A., in 1953,

- [iiis] 894 No. equity shares of Rs 100 each without payment in cash to American Cyanamid Co., U.S.A., in 1961,

- [ivs] 10,329 No. of Equity shares of Rs 100 each at a premium of Rs 163.89 per shares to The Atul Products Ltd., during 1961 & 1962,

- [vs] 997 No. of Equity shares of Rs 100 each without payment in cash to American Cyanamid Co., U.S.A., in 1962,

- [vis] 13,482 No. of Equity shares of Rs 100 each at a premium of Rs 55.80 per share to The Atul Products Ltd., & 12,884 No. of equity shares of Rs 100 each without payment in cash to American Cyanamid Co., U.S.A., in 1963 and

- [viis] 740 No. of Equity shares of Rs 100 each for cash in 1964.

1974

- 70,146 bonus shares issued on 18.3.1975 in prop. 1:1.

1979

- During June, the Comp. offered for sale 6,83,924 No. of Equity shares [4,55,949 No. of Equity shares held by American Cyanamid Co., U.S.A. & 2,27,975 No. of Equity shares held by Atul Products Ltd.s] Rs 10 each at a premium of Rs 12 per share to the resident Indian nationals. Out of these shares, 30,000 shares were reserved for subscription by employees of Comp. & 6,53,924 shares offered to the public. After the offer for sale, the inter-connections of the Comp. with The Atul Products Ltd., was severed under the MRTP Act.

- 3,15,657 bonus shares issued on 12.1.1979 in prop. 9:4. Shares subdivided on 22.1.1979. Authorised capital increased effective from 21.2.1979.

1981

- The products manufactured in organophosphate plant were 'THIMET', 'ABATE' & 'ACCOTHION'.

1987

- During September-October, out of its holding of 25,07,721 No. of equity shares in the Company, the American Cyanamid Co., U.S.A., offered to the resident Indian nationals 4,08,221 No. of Equity shares at a premium of Rs 20 per share to reduce its holding in the Company. These shares were offered as follows:

- [is] 2,60,304 shares to the existing resident Indian equity shareholders excluding Gujarat Industrial & Investment Corporation Ltd., & Ameer Trading Corporation Ltd.,

- [iis] 78,696 shares to the shareholders of Atul Products Ltd.,

- [iiis] 50,000 shares to UTI and

- [ivs] 19,221 shares to business associates of Company.

- The Comp. issued 6,90,510 No. of equity shares at a premium of Rs 20 per share to the resident Indian nationals simultaneously with the offer for sale of shares during September-October is as follows:

- [is] 2,18,443 shares to resident Indian equity shareholders excluding Gujarat Industrial and Investment Corporation Ltd., & Ameer Trading Corporation Ltd.,

- [iis] 4,37,542 shares to shareholders of Atul Products Ltd., and

- [iiis] 34,525 shares to employees [including Indian working directors/workers of Company. Thus along with the offer for sale, a total of 4,78,747 shares were offered as rights to the shareholders in proportion 7:10 besides offer to the other categories.

1988

- A new 45KL stainless steel fermentor was installed. A new antibiotic cynomycin & a pediatric suspension 'Penetrin' were introduced.

- The Comp. obtained a licence for manufacture of two million cynomycin capsules.

1989

- An industrial licence was received in February for manufacture of 150 tonnes of aeropromoter flocullants & collectors.

1990

- 'PROTON' an effective herbicide was launched by crop protection chemicals division.

- Government approval was received for manufacture of loxapine [an anti-psychotic agents].

1994

- The Agricultural products division launched Azodrin & Ripcord in the agrochemical market. A new product by name Tussivil [cough syrups] was launched.

1996

- Approvals were received for scheme for arrangement between Cyanamid Agro limited and Cyanamid India Ltd., & also for Wyeth Laboratories Ltd., John Wyeth [Indias] limited & Wyeth [Indias] Ltd in the Cyanamid India limited The scheme became effective from September 12, 1997 & the Agro undertaking of Comp. was to be transferred to and vested in Cyanamid Agro limited On amalgamation of Wyeth Companies with the company, the name of Comp. changed to 'Wyeth Lederle Ltd.'

1997

- Cyanamid India Limited, Cyanamid Agro Limited & the three Wyeth companies are being amalgamated with a view to bifurcating their business into two areas, agricultural products & pharmaceutical products under two companies.

- The Scheme of Amalgamation will position Wyeth Lederle Limited as the tenth largest pharmaceutical Comp. in India.

1998

- Wyeth Lederle India will be adding an anti-meningitis vaccine to its drugs portfolio. The vaccine, expected to be launched in a month, will combat HIB meningitis.

- The Comp. launched a vaccine for meningitis which is witnessing a 35 per cent plus growth rate.

1999

- Pharmaceutical major, Wyeth Lederle, is expanding its vaccines business as the Comp. is currently set to launch new vaccines in India. The Comp. had recently launched Pnu-Immune 23, a product to counters bacteria causing Pn.

- Pharma multinational Wyeth Lederle is exploring the possibility of setting up a greenfield unit for manufacturing formulations.

- The Comp. has two manufacturing facilities in Valsad [Gujarats] and Ghatkopar [Maharashtras].

2000

- Wyeth Lederle & Cyanamid Agro are subsidiaries of American Home Products Corporation.

- Wyeth has two manufacturing facilities in Pakistan.

- The Comp. is introducing `Premelle' & `Premelle Cycle', a hormone replacement therapy [HRTs] in India.

- The Comp. has signed agreements with NSDL, CDSL & Tata Consultancy Services, R&T agent, for dematerialisation of company's equity shares.

- The Board has apppointed Mr. R.A. Shah as Director & Chairman, Mr. S. Kumaraswamy as Director.

- The Comp. to launch in the current year Zosyn, a hospital antibiotic for severe infections, & an oncology product, which increases the platelet count for patients under chemotherapy treatment.

- Wyeth Lederle has launched Premelle & Premelle Cycle, pills meant for hormone replacement therapy.

2002

-The Wyeth Lederle agreed to amalgamate Geoffrey Manners and Co with itself.

-Mr.A.W Khandekar has given his resignation as director of company.

-Wyeth Lederly Ltd has inaugurated its new manufacturing facility at Verna, Goa.

-Changes in the Management of Wyeth Lederly: 1. Mr.Sunil Lalbhai appointed as Additional Director. 2. Mr.B J Poussot & Mr.H.F Bhabha ceased to be the director. 3. Mr.M H Bhabha appointed as Alternate to Mr.M M Larsen.

-Wyeth Lederly agreed to amalgamate Geoffrey Manners and Co. with itself.

-Wyeth as set up high-tech solid dosage plant at Goa. The Comp. has shutdown its formulations unit at Ghatkopar in Mumbai

-Wyethe Lederly has shifted its Registered Office to RBC, Mahindra Towers, 4thfloor A Wing , De G M Bhosale Road, Worli, Mumbai - 400 018.

-Wyeth Lederly has obtained the environment ministry approval to market its genetically modified drug Mylotarg, for treating relapse cases of CD 33 positive acute myeloid Leukamia.

2007

- Wyeth Ltd has informed that the Board of Directors of Comp. at its meeting held on October 27, 2007, has appointed Mr. Ashish Dalal, as an Additional Director. Mr. Ashish Dalal is a Non-Executive Independent Director.